Sydnexis, Inc., a biopharmaceutical company focused on developing a novel low-dose atropine formulation to treat pediatric progressive myopia (PPM), today announced new data from comprehensive ...
STAR randomized 847 US/European patients (3–14 years; -0.50 to -6.00 D) 1:1:1 and demonstrated primary endpoint success at 36 ...
Stocktwits on MSN
Theriva™ Biologics reports full-year 2025 operational highlights and financial results
Advancing clinical development of VCN-01 for pancreatic ductal adenocarcinoma and retinoblastoma – – Licensed SYN-020 to ...
The latest announcement is out from Grand Pharmaceutical Group Limited ( (HK:0512)). Grand Pharmaceutical Group has secured approval from China’s National Medical Products Administration for GPN01768, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results